Brief: Antengene Got NMPA Approval For Phase III Clinical Trial Of Selinexor
12/05/2021 16:10
May 12 (Reuters) - Antengene Corporation Ltd 6996.HK :
* GOT NMPA APPROVAL OF IND APPLICATION FOR PHASE III
CLINICAL
TRIAL OF SELINEXOR IN ADVANCED OR RECURRENT ENDOMETRIAL CANCER
Source text for Eikon: ID:nHKS7kzQk3
Further company coverage: 6996.HK
((reuters.briefs@thomsonreuters.com))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106